Drug Trial Radar · NCT04429191
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jul 8, 2020
Primary completion
Jun 13, 2023
Study completion Jun 13, 2023
Sponsor
- Lead sponsor
- Jasper Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.
Conditions
- MYELODYSPLASTIC SYNDROME; MDS
- ACUTE MYELOID LEUKEMIA; AML
Interventions
Humanized anti-CD117 Monoclonal Antibody (JSP191)Biological
Procedure: single intravenous infusion of JSP191 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects experiencing adverse events and serious adverse events will be assessed.Time frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)
- The number of dose limiting toxicities will be assessed.Time frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)
- The type of dose limiting toxicities will be assessed.Time frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
Stanford University
Stanford, California
Rush University Medical Center
Chicago, Illinois
Oregon Health & Science University
Portland, Oregon
Huntsman Cancer Institute - University of Utah
Salt Lake City, Utah
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.